Copertina

Miniaturized drug sensitivity and resistance test on patient-derived cells using Droplet-Microarray

Testing the sensitivity of patient-derived tumor cells ex vivo can potentially help determining the appropriate treatment for each patient and spot the development of resistance to a given therapy. The number of cells obtainable from a biopsy is, however, often insufficient for performing ex vivo te...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Popova, Anna A. (Autore) , Dietrich, Sascha (Autore) , Huber, Wolfgang (Autore) , Reischl, Markus (Autore) , Peravali, Ravindra (Autore) , Levkin, Pavel (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: June 2021
In: SLAS technology
Year: 2021, Volume: 26, Fascicolo: 3, Pages: 274-286
ISSN:2472-6311
DOI:10.1177/2472630320934432
Accesso online:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/2472630320934432
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2472630322011049
Testo
Note sull'autore:Anna A. Popova, Sascha Dietrich, Wolfgang Huber, Markus Reischl, Ravindra Peravali, and Pavel A. Levkin
Descrizione
Riassunto:Testing the sensitivity of patient-derived tumor cells ex vivo can potentially help determining the appropriate treatment for each patient and spot the development of resistance to a given therapy. The number of cells obtainable from a biopsy is, however, often insufficient for performing ex vivo tests in conventional microtiter plates. Here, we introduce a novel Droplet-Microarray platform based on a hydrophilic-superhydrophobic patterned surface that enables screenings using only 100 cells and 30 picomoles of a drug per individual nanoliter-sized droplet. We demonstrate that the dose-response of as few as 100 primary patient-derived chronic lymphocytic leukemia (CLL) cells to anticancer compounds on the Droplet-Microarray platform resembles the dose-response obtained in 384-well plates requiring 20,000 tumor cells per experiment. The extremely miniaturized Droplet-Microarray platform thus carries great potential for ex vivo drug sensitivity and resistance tests on patient-derived tumor cells and potentially for implementing such tests in medical practice of precision medicine.
Descrizione del documento:Elektronische Reproduktion der Druck-Ausgabe
Online verfügbar: 28. März 2022
Gesehen am 23.04.2026
Descrizione fisica:Online Resource
ISSN:2472-6311
DOI:10.1177/2472630320934432

Documenti analoghi